{
  "main_header": {
    "sid": 229993,
    "name": "Neuland Labs.",
    "stock_name": "Neuland Labs.",
    "full_name": "Neuland Laboratories Ltd",
    "name_url": "stocks-analysis/neuland-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "22,623.35",
    "chg": 429.65,
    "chgp": "1.94%",
    "dir": 1,
    "prev_price": "22,193.70",
    "mcapval": "29,025.51 Cr",
    "mcap": "Small Cap",
    "scripcode": 524558,
    "symbol": "NEULANDLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE794A01010",
    "curr_date": "Aug 11",
    "curr_time": "",
    "bse_nse_vol": "88.91 k",
    "exc_status": "Active",
    "traded_date": "Aug 11, 2026",
    "traded_date_str": "2026 08 11",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/neuland-labs-229993-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Neuland Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-neuland-laboratories-ltd-latest-results-good-or-bad-3989938",
        "imagepath": "",
        "date": "2026-05-13 19:17:02",
        "description": "Neuland Laboratories Ltd has reported its Q4 FY26 financial results, showcasing significant quarter-on-quarter growth. The company achieved net sales of ₹776.25 crores, reflecting a 76.54% increase from the previous quarter, alongside a remarkable net profit of ₹212.67 crores, which represents a 424.21% rise compared to Q3 FY26. This quarter's performance marks a notable turnaround from the preceding quarter, driven by robust revenue growth and substantial improvements in operating margins, which reached 39.59%, the highest in at least seven quarters.\n\nHowever, when viewed in the context of the full fiscal year FY25, the overall performance presents a more complex picture. For the year, Neuland Laboratories reported a decline in revenues of 5.3% to ₹1,476.00 crores and a net profit decrease of 13.33% to ₹260.00 crores compared to FY24. This divergence between the strong quarterly results and the annual perf..."
      },
      {
        "title": "Neuland Laboratories Ltd Sees Robust Trading Activity Amid Sector Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-sees-robust-trading-activity-amid-sector-outperformance-3989076",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_most_active_equities_by_value_3989076.png",
        "date": "2026-05-13 10:00:07",
        "description": "Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier."
      },
      {
        "title": "Neuland Laboratories Ltd Opens 8.11% Higher in Sharp Gap Up, But Can the Technicals Support It?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neuland-laboratories-ltd-opens-strong-with-significant-gap-up-reflecting-positive-market-sentiment-3989062",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NeulandLaborato_gapup_3989062.png",
        "date": "2026-05-13 09:50:07",
        "description": ""
      }
    ],
    "total": 15,
    "sid": "229993",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/neuland-laboratories-229993"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "07-Aug-2026",
      "details": "Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Aug-2026",
      "details": "Copy of Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "05-Aug-2026",
      "details": "Investor Presentation on the Financial Results of the Company for the quarter ended June 30 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Neuland Laboratories Ltd has declared <strong>340%</strong> dividend, ex-date: 24 Jul 26",
          "dt": "2026-07-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Neuland Laboratories Ltd has announced <strong>4:25</strong> rights issue, ex-date: 13 Aug 14",
          "dt": "2014-08-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Are Neuland Laboratories Ltd latest results good or bad?

2026-05-13 19:17:02

Neuland Laboratories Ltd has reported its Q4 FY26 financial results, showcasing significant quarter-on-quarter growth. The company achieved net sales of ₹776.25 crores, reflecting a 76.54% increase from the previous quarter, alongside a remarkable net profit of ₹212.67 crores, which represents a 424.21% rise compared to Q3 FY26. This quarter's performance marks a notable turnaround from the preceding quarter, driven by robust revenue growth and substantial improvements in operating margins, which reached 39.59%, the highest in at least seven quarters. However, when viewed in the context of the full fiscal year FY25, the overall performance presents a more complex picture. For the year, Neuland Laboratories reported a decline in revenues of 5.3% to ₹1,476.00 crores and a net profit decrease of 13.33% to ₹260.00 crores compared to FY24. This divergence between the strong quarterly results and the annual perf...

Read More

Neuland Laboratories Ltd Sees Robust Trading Activity Amid Sector Outperformance

2026-05-13 10:00:07

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier.

Read More

Neuland Laboratories Ltd Opens 8.11% Higher in Sharp Gap Up, But Can the Technicals Support It?

2026-05-13 09:50:07

Read More

View All News